## Original findings

1. **Critical — Ozonetel dependency:** **Partially Resolved.** Phase 0 makes SDK/commercial proof, webhook contract, and device PoC blocking before final call-work estimate; owner, decision date, fallback, separate discovery estimate still absent.

2. **Critical — Super Doctor escalation:** **Partially Resolved.** Immutable audit, named/manual destination, queue removal, acknowledgement added; receiving owner, SLA, system, retry, resolution remain open.

3. **Critical — HA/CSR/Ops handoffs:** **Partially Resolved.** Contract shape now requires trigger, payload, acknowledgement, timeout/retry, failure UI; destination schemas and receiving-team contracts still open.

4. **Major — missing submission/handoff state model:** **Resolved.** `submitting`, submission failure, handoff pending/accepted/failed, recovery, reconciliation now defined.

5. **Major — medicine mutation authority:** **Partially Resolved.** Phase 1 exit gate requires Product/Medical confirmation; authority itself still unconfirmed.

6. **Major — diagnosis/allergy contract:** **Partially Resolved.** Explicit allergy values and structured diagnosis fields added; taxonomy source, clinical sign-off, locking/amendment policy remain gated/open.

7. **Major — reject taxonomy/policy:** **Partially Resolved.** Draft status, compliance sign-off gate, routing shape, audit expectations now explicit; Truemeds-approved taxonomy and receiving contracts remain open.

8. **Major — substitution pricing conflict:** **Resolved.** PRD now permits read-only same-salt name/price delta only for consent conversation; no merchandising or pricing write-back.

9. **Major — RN/mobile-shell scope hidden:** **Resolved.** Web UI, native calling, backend, QA split into separate workstreams; native-host vs RN ADR now explicit.

10. **Major — metrics/release gates undefined:** **Partially Resolved.** Launch-gate structure added; owners, windows, thresholds, dashboard remain open before rollout.

11. **Minor — clinical-risk interaction/error patterns:** **Partially Resolved.** Native-call, handoff-failure, reconnect, accessibility risks expanded; full interaction/QA specs still deferred.

12. **Minor — duplicated decision documentation:** **Still Open.** PRD remains repetitive across workflow, requirements, architecture, and phase sections.

## New Critical/Major finding

- **Critical — reject flow still violates locked valid-call gate.** Revised R1 allows Reject after a “documented no-answer/failed-dial attempt,” while locked truth requires a completed valid call before any final operational CTA. Either require valid-call completion for Reject, or explicitly approve/document a gate exception.

## Verdict

**Ready for Phase 0 discovery and separate workstream estimation only. Not ready for final Phase 1 delivery estimate or implementation commitment** until Phase 0 blockers close and Reject gate conflict resolves.